PhytoMedical Technologies, Inc.
OTCBB: PYTO.OB
Phytomedical Technologies (formerly Enterprise Technologies) is a biopharmaceutical firm that is researching and developing plant-derived pharmaceutical and nutraceutical compounds intended to be used as a treatment for obesity and cachexia. PhytoMedical's first compound, BDC 03, contains active elements that have been successful in reducing body fat and increasing muscle mass during studies, without a dramatic change in a patient's diet or exercise activity. The compound holds promise for individuals suffering from cachexia. Cachexia (dramatic loss of fatty tissue, muscle tissue, and bone) is one of the life-threatening aspects of AIDS and cancer. Chairman Harmel Rayat owns 69% of the company.